Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03269695|
Recruitment Status : Recruiting
First Posted : September 1, 2017
Last Update Posted : November 29, 2018
|Condition or disease||Intervention/treatment||Phase|
|Ulcerative Colitis||Drug: PF-06687234||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||76 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||A Phase 2a, Randomized, Double-blind, Placebo-controlled Study To Evaluate The Efficacy, Safety, Tolerability And Pharmacokinetics Of Pf-06687234 As Add-on Therapy To Infliximab In Active Ulcerative Colitis Subjects Who Are Not In Remission (BUILD UC)|
|Actual Study Start Date :||December 20, 2017|
|Estimated Primary Completion Date :||February 26, 2020|
|Estimated Study Completion Date :||February 26, 2020|
PF-06687234 subcutaneous (SC) weekly (QW) x 12 doses
Placebo Comparator: Placebo
PF-06687234 Placebo SC QW x 12 doses
- Proportion of subjects in Clinical Remission [ Time Frame: Week 12 ]Clinical remission defined by a modified Mayo Score with an endoscopic subscore less than or equal to 1, stool frequency subscore less than or equal to 1 and rectal bleeding subscore = 0
- Proportion of subjects with endoscopic improvement [ Time Frame: Week 12 ]Endoscopic improvement defined as decrease of 1 point in Mayo endoscopy score or an absolute endoscopy score of 1 or less.
- Mean change from baseline at Week 12 in Geboes histology score [ Time Frame: Baseline, Week 12 ]Mean change from baseline at Week 12 in Geboes score.
- Proportion of subjects with a clinical response [ Time Frame: Week 12 ]Clinical response defined with a decrease from baseline of at least 3 points in total Mayo score with at least 30% change, accompanied by at least one point decrease or absolute score of 0 or 1 in rectal bleeding subscore.
- Proportion of subjects with change from baseline in partial Mayo Score of 2 or less with no individual subscore >1 [ Time Frame: Weeks 2, 4, 6, 8, 12 ]Proportion of subjects with partial Mayo score <=2 with no individual subscore of > 1 at Week 2, 4, 6, 8 and 12
- Serum concentrations of PF 06687234 [ Time Frame: Baseline through Week 12 ]Measure serum concentration of PF-06687234 at baseline, Week 1, 3, 7, 11, 12, and 16
- Incidence of the development of HAFAs and Nabs against PF 06687234. [ Time Frame: Baseline through Week 16 ]Measure HAFA and neutralizing antibody against IL10 at screen, baseline, Week 3, 7, 11, 12, and 16
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03269695
|Contact: Pfizer CT.gov Call Center||1-800-718-1021||ClinicalTrials.gov_Inquiries@pfizer.com|
Show 48 Study Locations
|Study Director:||Pfizer CT.gov Call Center||Pfizer|